- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02342613
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
April 24, 2024 updated by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes Derived From Patients With Bone Marrow Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis.
This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation (alloHCT) for patients with hematologic malignancies with bone marrow involvement of their relapsed disease.
These MILs will be derived from the bone marrow of the relapsed patient who had previously received post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis (PTCy-MILs).
A bone marrow aspiration will be performed on the patient to collect ~200ml of marrow for ex vivo expansion.
During this expansion process, T cells will be activated and expanded by co-stimulation with anti-CD3/anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads.
Patients will be treated with salvage therapy while this ex vivo expansion is ongoing.
After the simultaneous salvage therapy and ex vivo expansion, the activated PTCy-MILs will be reinfused.
Patients will be monitored with the primary objective being the feasibility of expanding to targeted dose levels activated PTCy-MILs that do not cause grade III-IV acute GVHD within the first 90 days after PTCy-MIL infusion.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Primary Objectives:
- Feasibility of generating activated PTCy-MILs in patients with relapsed disease involving the bone marrow.
- Toxicity of PTCy-MILs, specifically the rate of grade III-IV acute GVHD within the first 90 days after PTCy-MIL infusion.
Secondary Objectives
- Determination of an optimal safe dose for PTCy-MILs.
- Immunologic characterization of the PTCy-MIL product before and after expansion.
- Immune reconstitution after treatment with PTCy-MILs.
- Incidence and severity of chronic GVHD.
- Clinical responses (complete remissions, partial remissions, stable disease) as measured by criteria specific for the particular disease type.
- Progression-free and overall survival.
Study Type
Interventional
Enrollment (Estimated)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years old
- Bone marrow relapse of a hematologic malignancy ≥6 months after alloHCT using PTCy
- Donor CD3+ chimerism ≥ 30% measured in peripheral blood or bone marrow
- ECOG performance status ≤ 2 or Karnofsky performance scale ≥ 70%.
- Off all immunosuppressive drugs for 2 weeks prior to the PTCy-MILs collection.
- Expectation of ability to safely undergo salvage treatment appropriate for the patient's malignant disease type as determined by the treating hematologist/ oncologist.
Exclusion Criteria:
- Most recent alloHCT not utilizing PTCy.
- Active GVHD requiring treatment.
- Immunosuppression use within 28 days of PTCy-MIL infusion if prior grade II-IV acute GVHD.
- Creatinine ≥ 2.5, total bilirubin > 3 times the upper limit of normal (ULN), or AST/ALT > 3 times the ULN.
- HIV-1/2 or HTLV-1/2 positivity.
- Life expectancy ≤ 90 days even with aggressive treatment, as determined by the treating hematologist/oncologist, which would preclude assessment of toxicity of PTCy-MILs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MILs treatment
Patients treated with the activated PTCy-MILs
|
The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site.
Each of the bags will be infused at a rate of approximately 10 ml per minute.
The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of generating activated marrow infiltrating lymphocytes (MILs) from participants previously treated with post-transplantation cyclophosphamide (PTCy) (PTCy-MILs) who have relapsed disease involving the bone marrow
Time Frame: 90 days
|
Feasibility is measured as the number of participants who achieve: 1) The successful obtaining of PTCy-MILs; 2) The expansion of PTCy-MILs to at least 70% of the assigned dose level; 3) Successful infusion of PTCy-MILs; 4) The absence of grade III-IV acute graft-versus-host-disease (GVHD) for 90 days after PTCy-MILs infusion.
Acute GVHD is defined by the Modified Keystone Criteria.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal safe dose for PTCy-MILs
Time Frame: 90 days
|
Optimal safe dose is defined as the maximal MILs cell dose that can be expanded in at least 70% of patients at which upon administration does not exacerbate grade III/IV GVHD
|
90 days
|
Immunologic characterization of the PTCy-MIL product before and after expansion
Time Frame: up to 3 years
|
Amount of MILs with expression of CD3, CD4, Cd8, CXCR4, CD45RO, CD62L, CD107a, FasL, markers of exhaustion and T-cell inactivation as identified by multi-color flow cytometry and functional studies of alloMILs and T-cell response.
|
up to 3 years
|
Number of participants who experience chronic GVHD
Time Frame: up to 2 years post-transplant
|
Chronic GVHD is defined by National Institutes of Health (NIH) criteria.
|
up to 2 years post-transplant
|
Clinical Response
Time Frame: up to 3 years
|
Number of participants with complete remission (CR), partial remission (PR) and stable disease (SD) as assessed by bone marrow examination, CBC with differential, serum chemistries, cytogenetics and disease-specific molecular studies
|
up to 3 years
|
Progression-Free Survival
Time Frame: up to 3 years
|
Time from day of PTCy-MILs infustion to progression/relapse of disease or death from any cause, whichever occurs first
|
up to 3 years
|
Overall Survival
Time Frame: up to 3 years
|
Time alive from the day of PTCy-MILs infusion to death from any cause
|
up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Leo Luznik, MD, Sidney Kimmel Cancer Center at Johns Hopkins
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 28, 2015
Primary Completion (Actual)
November 29, 2023
Study Completion (Actual)
March 31, 2024
Study Registration Dates
First Submitted
January 15, 2015
First Submitted That Met QC Criteria
January 15, 2015
First Posted (Estimated)
January 21, 2015
Study Record Updates
Last Update Posted (Actual)
April 25, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- J1484
- IRB00039074 (Other Identifier: JHM IRB)
- P01CA153962 (Other Grant/Funding Number: NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancies
-
Cooperative Study Group A for HematologyCompletedHEMATOLOGIC MALIGNANCIESKorea, Republic of
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Washington University School of MedicineRecruitingPediatric Hematologic MalignanciesUnited States
-
Medical College of WisconsinCompletedMalignancies, HematologicUnited States
-
Sinocelltech Ltd.RecruitingRelapsed or Refractory Hematologic MalignanciesChina
-
Vanda PharmaceuticalsUnknownRelapsed or Refractory Hematologic MalignanciesUnited States
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
-
King Faisal Specialist Hospital & Research CenterCompletedTransplantation for Hematologic MalignanciesSaudi Arabia
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
Constellation PharmaceuticalsNot yet recruitingSolid Tumor | Hematologic Malignancy | Advanced Malignancies
Clinical Trials on Activated PTCy-MILs
-
Shanghai General Hospital, Shanghai Jiao Tong University...Completed
-
Ajou University School of MedicineCompletedOral Surgery | Maxillofacial Surgery
-
Shanghai Jiao Tong University School of MedicineShanghai Clinical Research CenterNot yet recruiting
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownProphylaxis | Graft-versus-host-diseaseChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsTaiwan, United Kingdom, Thailand, Serbia, Croatia, Italy, Poland, Romania, Hungary, Malaysia, United States, Austria, Brazil, Greece, Japan, Puerto Rico, Russian Federation, South Africa, Turkey
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BUnited States, Spain, Taiwan, Turkey, Poland, Croatia, Italy, Malaysia, Brazil, United Kingdom, Hungary, Israel, Thailand, Japan, South Africa, Canada, France, Argentina
-
Novo Nordisk A/SCompletedSpinal Fusion | Acquired Bleeding DisorderUnited States
-
Novo Nordisk A/SCompletedAcquired Bleeding Disorder | Intracerebral HaemorrhageJapan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Glanzmann's DiseaseJapan